ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of the Natural Progression of Interstitial Lung Disease (ILD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00470327
Recruitment Status : Recruiting
First Posted : May 7, 2007
Last Update Posted : April 30, 2018
Sponsor:
Collaborator:
Idiopathic Pulmonary Fibrosis Clinical Research Network
Information provided by (Responsible Party):
University of Chicago

Brief Summary:
We propose to acquire data and blood samples on all patients being cared for by the Interstitial Lung Disease (ILD) program. Additionally, we will collect data and blood samples from a control group for comparator purposes. In doing so, we will be able to describe the "phenotypic" expression of these diseases.

Condition or disease
Interstitial Lung Diseases Idiopathic Pulmonary Fibrosis Sarcoidosis Connective Tissue Disorder

Study Type : Observational
Estimated Enrollment : 4000 participants
Observational Model: Other
Time Perspective: Prospective
Official Title: A Study of the Natural Progression of Interstitial Lung Disease (ILD)
Actual Study Start Date : September 2005
Estimated Primary Completion Date : December 2020
Estimated Study Completion Date : December 2025





Primary Outcome Measures :
  1. Natural history of course of disease in patients with Interstitial lung disease (ILD) [ Time Frame: Yearly ]
    We assess mortality roughly yearly but duration is unlimited


Biospecimen Retention:   Samples With DNA
blood


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Subjects cared for in the ILD (Interstitial Lung Disease)clinic
Criteria

Inclusion Criteria:

  • Interstitial lung disease

Exclusion Criteria:

  • Does not have Interstitial lung disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00470327


Contacts
Contact: Spring Maleckar 773-834-4053

Locations
United States, Illinois
University of Chicago Recruiting
Chicago, Illinois, United States, 60637
Contact: Mary E Strek, MD    773-702-3609    mstrek@medicine.bsd.uchicago.edu   
Principal Investigator: Mary E Strek, MD         
Sponsors and Collaborators
University of Chicago
Idiopathic Pulmonary Fibrosis Clinical Research Network
Investigators
Principal Investigator: Mary E Strek, MD University of Chicago

Responsible Party: University of Chicago
ClinicalTrials.gov Identifier: NCT00470327     History of Changes
Other Study ID Numbers: 14163A
First Posted: May 7, 2007    Key Record Dates
Last Update Posted: April 30, 2018
Last Verified: April 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: We will share coded data with no PHI

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by University of Chicago:
Interstitial lung diseases
idiopathic pulmonary fibrosis
Sarcoidosis
mRNA and cytokine expression

Additional relevant MeSH terms:
Lung Diseases
Lung Diseases, Interstitial
Fibrosis
Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Idiopathic Interstitial Pneumonias
Sarcoidosis
Connective Tissue Diseases
Pathologic Processes
Respiratory Tract Diseases
Lymphoproliferative Disorders
Lymphatic Diseases